Flagship Biosciences is at the forefront of spatial biology, leveraging advanced technologies to enhance biomarker and clinical development programs. Their SPATIAL Plex™ solutions integrate a team of scientists and bioinformaticians, supported by a legacy of pathology expertise, to provide comprehensive tissue analysis that is crucial for drug development. The company utilizes machine learning and artificial intelligence to streamline spatial analysis, collecting and analyzing extensive data points per cell. This innovative approach allows for the integration of spatial proteomic and genomic data, facilitating precise and reliable results in therapeutic development and translational science.

In addition to spatial biology, Flagship Biosciences excels in genomic analysis, offering a wide range of services including full genome sequencing, RNA sequencing, and spatial transcriptomics. Their state-of-the-art technologies and methodologies ensure high-quality results, while their expertise in multiplex immunohistochemistry (IHC) and in situ hybridization enables the simultaneous detection of multiple biomarkers in a single sample. The company’s commitment to quality is underscored by its CLIA certification and CAP accreditation, ensuring that their laboratory testing and analysis meet the highest standards. Through strategic partnerships and a consultative approach, Flagship Biosciences aims to deliver customized data solutions that support clinical trials and advance patient outcomes.

United States

Flagship Biosciences is a leader in spatial biology and biomarker analysis, bringing innovative approaches to clinical research and drug development. The company delivers the most accurate and informative data available in the field of spatial biology and biomarker services.

Flagship Biosciences

Company Details